FOR IMMEDIATE RELEASE

September 1, 2010 (Irvine, California) - BioMedGPS, a provider of real-time online business intelligence and dynamic decision-making tools for life science executives, announces the launch of a new SmartTRAK OrthoBio module focused exclusively on biologic and biomaterial products for soft tissue replacement in Sports Medicine. This new addition to the SmartTRAK OrthoBio database provides detailed and continuously updated profiles on 48 companies (public, profit, non-profit) and over 75 biologic and biomaterial products on the market or under development for ligament, tendons and soft tissue reinforcement or replacement of the knee, shoulder and extremities. Also provided are detailed Market Profiles of the rotator cuff augmentation and knee ligament replacement markets with 5-year US sales and procedure volumes forecasts, competitive market shares, and regulatory and reimbursement information.

The US market for soft tissue patch materials primarily used for rotator cuff augmentation is estimated at $43 million in 2010, and projected to reach $64 million in 2014, according to SmartTRAK. According to the analysis, patches are used in only 4% of all rotator cuff repair procedures performed today owing to the difficulty in implanting them arthroscopically. Until products are modified or new arthroscopic techniques developed, use of patch materials for this indication will be limited. With close to 25 patches on the US market (many approved as surgical mesh without a specific indication for use), patches are finding expanded application in foot/ankle and hand/wrist soft tissue surgery. The SmartTRAK OrthoBio database provides detailed profiles of soft tissue products on the market as well as under development that can be filtered by company ownership, technology (allogeneic, biologic, synthetic, composite, growth factor, stem cells), regulatory status (US, OUS), and strategic alliance.

The use of allografts for knee ligament reconstruction represents the largest segment of the Soft Tissue market with sales projected to reach close to $300 million in 2014, as the percentage of allografts used as off-the-shelf anterior cruciate ligament (ACL) grafts increases. It is estimated that over 26% of ACL procedures performed in the US in 2010 will employ an allograft and this percentage will grow to over 36% by 2014, according to the SmartTRAK ACL Market Overview. Leading stakeholders in this market include non-profit tissue banks which have formed distribution agreements with leading sports medicine companies or have established their own direct presence in this arena.

“More than 30 privately held companies developing biologic and biomaterial soft tissue replacement products are profiled in real-time in SmartTRAK,” reports Sharon O’Reilly, Founder, President and CEO of BioMedGPS, the developer of the SmartTRAK Online Business Intelligence System. “Any company interested in expanding their Sports Medicine business can quickly identify opportunities with emerging companies and products for partnering, acquisition and strategic alliance by searching the SmartTRAK OrthoBio online database.”

SmartTRAK is an innovative interactive online market intelligence platform designed to help medical device executives make faster, smarter and more cost-effective business decisions. Designed to replace print market and technology reports widely used in the industry today, the powerful SmartTRAK Online Business Intelligence will transform the delivery of medical device business information from static data to real-time information and analysis. SmartTRAK tracks emerging companies, competitive developments, regulatory approvals, and strategic alliances, and presents this information in concise individual market, company and product profiles that are updated as industry developments occur to provide users with a current "snapshot" of a medical device industry segment. SmartTRAK allows users to search, sort, store and share information—increasing the productivity of business/corporate development, marketing, market research, R&D and other device executives, and saving companies money.

Contact BioMedGPS to schedule a live demo with your team.

About BioMedGPS, LLC
Founded by Sharon O'Reilly, Founder and former CEO of Medtech Insight, BioMedGPS provides online business intelligence and dynamic decision-making tools specifically designed for life science executives. In addition to SmartTRAK, the Company also holds focused Strategic Partnering and Investment Conferences, and provides medical device market expertise via its Consulting Group.

CONTACT:
Sharon O’Reilly or Tracy Neilssien
949-559-5511
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.biomedgps.com